Oncology

We are leading a revolution in oncology to redefine cancer care




We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.



Clinical Strategy

Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We think differently about the underlying genetic causes of cancer. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.





Medicines: Portfolio and Pipeline


With our portfolio, our pipeline and our people, we aim to revolutionise cancer care. We follow the science, wherever it takes us, in pursuit of the best medicines. Through this relentless quest for innovation, we have created one of the most diverse portfolios and pipelines in the industry – encompassing molecules and modalities designed to preferentially kill cancer cells, at every stage of disease.

 


Key disease areas

Our focus is on some of the most hostile and hard-to-treat cancers. By understanding the complexities of cancer, we hope to achieve life-changing benefits for patients.


Lung Cancer


Breast Cancer


Ovarian Cancer



Haematology


Prostate Cancer


Bladder Cancer



Liver Cancer


Pancreatic Cancer


Cervical Cancer



Our scientific platforms

Our advances across our six scientific platforms have helped to improve patient outcomes. Further developments in epigenetics and across cell, gene and combination therapy hold the promise of new possibilities.






Our Oncology medicines

Our medicines are approved in individual countries for specific uses, and the information we provide for patients is governed by local regulations. In some countries, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. However, please note that in some countries we are not permitted to provide very much, or sometimes any, information on our prescription medicines, so you should only obtain information from trustworthy sources, and always ask a healthcare professional for advice about medicines.


Arimidex 

anastrozole

Calquence

acalabrutinib

Casodex, Cosudex

bicalutamide

Enhertu

trastuzumab deruxtecan

Faslodex 

fulvestrant

Imfinzi

durvalumab

Iressa

gefitinib

Koselugo

selumetinib

Lynparza

olaparib

Tagrisso

osimertinib

Zoladex

goserelin acetate implant



Our Oncology pipeline


Our industry-leading pipeline includes investigational therapies in various stages of clinical development – from approved medicines to earlier-stage molecules in clinical trials.

Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III or have been submitted for regulatory approval and may include assets that are launched in one or more major markets (removed when launched in all applicable major markets).


Oncology (as of 11 February 2021)

Phase I

Phase I

  • AZD0466 haematological and solid tumours
  • AZD1390 glioblastoma
  • AZD4573 haematalogical malignancies
  • AZD5305 solid tumours
  • AZD5991 haematalogical malignancies
  • AZD7648 haematological and solid tumours
  • AZD8701 solid tumours
  • Calquence (platform) PRISM relapsed/refractory aggressive non-hodgkin’s lymphoma
  • Calquence + ceralasertib haematological malignancies
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + CTx 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201 solid tumours
  • MEDI1191 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI5395 solid tumours
  • MEDI5752 + Axitinib advanced renal cell carcinoma
  • MEDI9253 solid tumours
  • Tagrisso + (Koselugo or savolitinib) TATTON advanced EGFRm non-small cell lung cancer

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx) metastatic pancreatic cancer
  • adavosertib ovarian cancer, solid tumours, uterine serous cancer
  • AZD2811 nanoparticle solid tumours, haematological malignancies
  • camizestrant (AZD9833) oestrogen receptor +ve breast cancer
  • capivasertib prostate cancer
  • Imfinzi (platform) BALTIC ES-SCLC refractory/resistant
  • Imfinzi (platform) COAST non small cell lung cancer
  • Imfinzi (platform) HUDSON post IO non-small cell lung cancer
  • Imfinzi (platform) NeoCOAST non-small cell lung cancer
  • Imfinzi + FOLFOX + bevacizumab COLUMBIA 1 1st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + imaradenant (AZD4635) + cabazitaxel prostate cancer
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + Lynparza ORION 1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer
  • Lynparza + ceralasertib VIOLETTE breast cancer
  • MEDI5752 solid tumours
  • Post-1L Tagrisso ORCHARD (platform) EGFRm non-small cell lung cancer
  • Tagrisso + savolitinib SAVANNAH advanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • capivasertib + CTx CAPItello-290 1st-line metastatic triple negative breast cancer
  • capivasertib + fulvestrant CAPItello-291 locally advanced (inoperable) or metastatic breast cancer
  • capivasertib# + abiraterone CAPItello-281 PTEN deficient metastatic hormone sensitive prostate cancer
  • Enhertu DESTINY-Breast01 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with T-DM1
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRT ADRIATIC 1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTx POSEIDON 1st-line non-small cell lung cancer
  • Koselugo/selumetinib SPRINT paediatric neurofibromatosis type-1
  • Lumoxiti 3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi DUO-E 1st-line endometrial cancer
  • Lynparza + Imfinzi + bevacizumab DUO-O 1st-line ovarian cancer
  • monalizumab + cetuximab INTERLINK-1 2L+ relapsed metastatic head and neck squamous cell cancer

LCM Projects

LCM Projects

  • Calquence ECHO 1st-line mantle cell lymphoma
  • Calquence ASCEND relapsed/refractory chronic lymphocytic leukaemia
  • Calquence ELEVATE-RR relapsed/refractory chronic lymphocytic leukaemia, high risk
  • Calquence ELEVATE-TN 1st-line chronic lymphocytic leukaemia
  • Calquence + R-CHOP ESCALADE 1st-line Diffuse Large B Cell Lymphoma
  • Calquence + venetoclax + obinutuzumab AMPLIFY 1st-line chronic lymphocytic leukaemia
  • Enhertu DESTINY-Breast03 HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • Enhertu DESTINY-Breast05 HER2-positive post-neoadjuvant high-risk breast cancer
  • Enhertu DESTINY-Breast06 post-ET HER2low/HR+ breast cancer 2L
  • Enhertu DESTINY-CRC01 HER2-expressing advanced colorectal cancer
  • Enhertu DESTINY-Gastric01 HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • Enhertu DESTINY-Gastric02 HER2-positive gastric cancer that cannot be surgically removed or has spread
  • Enhertu DESTINY-Lung01 HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer
  • Enhertu DESTINY-PanTumour01 HER2-expressing solid tumors
  • Enhertu DESTINY-PanTumour02 HER2-expressing solid tumors
  • Enhertu DESTINY-Breast02 HER2-positive, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1
  • Enhertu DESTINY-Breast04 HER2-low, unresectable and/or metastatic breast cancer subjects
  • Imfinzi CALLA locally-advanced cervical cancer
  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi PEARL 1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform) BEGONIA 1st-line metastatic triple negative breast cancer
  • Imfinzi (platform) MAGELLAN 1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CRT KUNLUN Locally advanced esophageal squamous cell carcinoma
  • Imfinzi + CRT PACIFIC-5 (China) locally-advanced (stage III) non-small cell lung cancer
  • Imfinzi + CTx MATTERHORN Neo-adjuvant/adjuvant gastric cancer
  • Imfinzi + CTx MERMAID-1 stage II-III adjuvant NSCLC
  • Imfinzi + CTx NIAGARA muscle invasive bladder cancer
  • Imfinzi + CTx TOPAZ-1 1st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvant AEGEAN locally-advanced (stage II-III) non-small cell lung cancer
  • Imfinzi + SoC CASPIAN 1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGF EMERALD-2 adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACE EMERALD-1 locoregional hepatocellular carcinoma
  • Imfinzi post-SBRT PACIFIC-4 stage I/II non-small cell lung cancer
  • Lynparza LYNK-003 platinum sensitive 1st-line colorectal cancer
  • Lynparza PROfound prostate cancer
  • Lynparza OlympiA gBRCA adjuvant breast cancer
  • Lynparza OlympiAD gBRCA metastatic breast cancer
  • Lynparza POLO pancreatic cancer
  • Lynparza SOLO-3 gBRCA PSR ovarian cancer
  • Lynparza (basket) MK-7339-002 / LYNK002 HRRm cancer
  • Lynparza + abiraterone PROpel prostate cancer
  • Tagrisso ADAURA adjuvant EGFRm non-small cell lung cancer
  • Tagrisso LAURA stage 3 EGFRm non-small cell lung cancer
  • Tagrisso + CTx FLAURA2 1st-line advanced EGFRm non-small cell lung cancer
  • Tagrisso +/- CTx neoadjuvant NeoADAURA stage II/III resectable EGFRm NSCLC


Collaboration in Oncology


Despite huge advances in cancer care over recent decades, we know there is still more to be achieved. We cannot do this alone; we know that outsmarting cancer requires a collective and collaborative approach. From drug discovery collaborations to commercial partnerships, we are sourcing new medicines, investing in the brightest minds and funding research across the globe, with a focus on maximising impact through shared knowledge and experience.

 


Patient Experience

Patients are at the heart of everything we do. Through relentless innovation and a commitment to scientific discovery we are catalysing changes in the practice of medicine to transform the patient experience. By working with the community, we can empower patients and caregivers, and are able to evolve the way cancer is treated by accelerating the uptake of the latest advancements.

Through collaborations with researchers, academia, healthcare providers, governments, industry and scientific organisations, patients and their families, we are uncovering unique insights on how we can establish new standards of screening, diagnostics and treatment.

 


In the spotlight



Our People & Culture

Making significant scientific and cancer care advancements requires courage, curiosity, collaboration, and a passion for learning which is why we encourage disruptive thinking where failure is an opportunity to learn. Our team shares a united vision and everything we do begins with the science and centres around patients. Our people are driven by our bold ambition and together we can grow and achieve excellence.

Our team doesn’t fit one mould and we foster an inclusive culture where diversity drives innovation and progress, by challenging assumptions and creating opportunities for new discoveries and creative solutions.



Meet our team




Our Resources



Latest news

Veeva ID: Z4-30595

Date of Prep: 3 February 2021